HomeCompareBCEL vs MRK

BCEL vs MRK: Dividend Comparison 2026

BCEL yields 2222.22% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BCEL wins by $26607504688.20M in total portfolio value
10 years
BCEL
BCEL
● Live price
2222.22%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26607504688.26M
Annual income
$24,443,703,761,807,280.00
Full BCEL calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — BCEL vs MRK

📍 BCEL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBCELMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BCEL + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BCEL pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BCEL
Annual income on $10K today (after 15% tax)
$188,888.89/yr
After 10yr DRIP, annual income (after tax)
$20,777,148,197,536,188.00/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, BCEL beats the other by $20,777,148,197,527,590.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BCEL + MRK for your $10,000?

BCEL: 50%MRK: 50%
100% MRK50/50100% BCEL
Portfolio after 10yr
$13303752344.16M
Annual income
$12,221,851,880,908,696.00/yr
Blended yield
91.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

BCEL
Analyst Ratings
4
Buy
4
Hold
Consensus: Buy
Price Target
$4.00
+4344.4% upside vs current
Range: $4.00 — $4.00
Altman Z
-37.6
Piotroski
3/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BCEL buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBCELMRK
Forward yield2222.22%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$26607504688.26M$57.7K
Annual income after 10y$24,443,703,761,807,280.00$10,113.78
Total dividends collected$26455115546.17M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$4.00$128.54

Year-by-year: BCEL vs MRK ($10,000, DRIP)

YearBCEL PortfolioBCEL Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$232,922$222,222.22$11,213$373.04+$221.7KBCEL
2$5,086,656$4,837,429.33$12,667$512.06+$5.07MBCEL
3$104,173,443$98,730,720.93$14,439$708.14+$104.16MBCEL
4$2,001,166,924$1,889,701,340.37$16,640$988.16+$2001.15MBCEL
5$36,067,485,611$33,926,237,001.88$19,432$1,394.07+$36067.47MBCEL
6$610,050,404,477$571,458,194,873.63$23,057$1,992.90+$610050.38MBCEL
7$9,686,139,336,337$9,033,385,403,546.24$27,889$2,894.79+$9686139.31MBCEL
8$144,409,519,569,037$134,045,350,479,156.38$34,518$4,286.29+$144409519.53MBCEL
9$2,022,243,856,495,371$1,867,725,670,556,501.50$43,912$6,494.35+$2022243856.45MBCEL
10$26,607,504,688,257,330$24,443,703,761,807,280.00$57,714$10,113.78+$26607504688.20MBCEL

BCEL vs MRK: Complete Analysis 2026

BCELStock

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.

Full BCEL Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this BCEL vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BCEL vs SCHDBCEL vs JEPIBCEL vs OBCEL vs KOBCEL vs MAINBCEL vs JNJBCEL vs ABBVBCEL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.